Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
34
ORMP Quote, Financials, Valuation and Earnings
Last price:
$2.37
Seasonality move
:
6.43%
Day range:
$2.35 - $2.40
52-week range:
$2.00 - $3.67
Dividend yield:
0%
P/E ratio:
21.64x
P/S ratio:
36.45x
P/B ratio:
0.61x
Volume:
61.6K
Avg. volume:
189.6K
1-year change:
--
Market cap:
$95.9M
Revenue:
$1.3M
EPS (TTM):
$0.11
Analysts' Opinion
-
Consensus RatingOramed Pharmaceuticals has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Oramed Pharmaceuticals has an estimated upside of 36.56% from its current price of $2.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.38.
Fair Value
-
According to the consensus of 0 analysts, Oramed Pharmaceuticals has 36.56% upside to fair value with a price target of -- per share.
ORMP vs. S&P 500
-
Over the past 5 trading days, Oramed Pharmaceuticals has underperformed the S&P 500 by -1.62% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Oramed Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Oramed Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Oramed Pharmaceuticals reported revenues of --.
Earnings Growth
-
Oramed Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Oramed Pharmaceuticals reported earnings per share of -$0.48.
Enterprise value:
-47.3M
EV / Invested capital:
--
Price / LTM sales:
36.45x
EV / EBIT:
-1.92x
EV / Revenue:
-17.49x
PEG ratio (5yr expected):
--
EV / Free cash flow:
5.96x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-1.90x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.7M | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$38.9M | -$21.6M | -$13.1M | -$2.9M | -$3.1M | |
| EBITDA | -$37.7M | -$16M | $24.9M | -$2.4M | -$3M | |
| Diluted EPS | -$0.94 | -$0.41 | $0.11 | -$0.08 | -$0.48 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $160.2M | $175.7M | $142.8M | |
| Total Assets | -- | -- | $164.4M | $230.9M | $165.1M | |
| Current Liabilities | -- | -- | $6.5M | $78.2M | $5.3M | |
| Total Liabilities | -- | -- | $11.3M | $82.7M | $9.6M | |
| Total Equity | -- | -- | $153.1M | $148.2M | $155.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$26.8M | -$16.9M | -$7.9M | -$694K | -$7.1M | |
| Cash From Investing | -$80.1M | -$91.8M | $120.4M | -$75.1M | -$34.3M | |
| Cash From Financing | $67.2M | $81.2M | -$75.8M | $74.5M | -$1.3M | |
| Free Cash Flow | -$26.9M | -$17.5M | -$7.9M | -$726K | -$7.1M | |
ORMP
Sector
Market Cap
$95.9M
$46.1M
Price % of 52-Week High
64.85%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
--
-30.52%
Beta (5-Year)
1.697
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.40
200-day SMA
Sell
Level
$2.43
Bollinger Bands (100)
Sell
Level
2.31 - 2.45
Chaikin Money Flow
Sell
Level
-70.1M
20-day SMA
Sell
Level
$2.43
Relative Strength Index (RSI14)
Sell
Level
47.99
ADX Line
Sell
Level
14.77
Williams %R
Neutral
Level
-76.6667
50-day SMA
Sell
Level
$2.38
MACD (12, 26)
Sell
Level
0.01
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
36M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.6773)
Buy
CA Score
(Annual)
Level (1.201)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-5.0395)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
Stock Forecast FAQ
In the current month, ORMP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ORMP average analyst price target in the past 3 months is --.
-
Where Will Oramed Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Oramed Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Oramed Pharmaceuticals?
Analysts are divided on their view about Oramed Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Oramed Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Oramed Pharmaceuticals's Price Target?
The price target for Oramed Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ORMP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Oramed Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ORMP?
You can purchase shares of Oramed Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Oramed Pharmaceuticals shares.
-
What Is The Oramed Pharmaceuticals Share Price Today?
Oramed Pharmaceuticals was last trading at $2.37 per share. This represents the most recent stock quote for Oramed Pharmaceuticals. Yesterday, Oramed Pharmaceuticals closed at $2.38 per share.
-
How To Buy Oramed Pharmaceuticals Stock Online?
In order to purchase Oramed Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 2.02% over the past day.
